

Mary O'Brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490713/publications.pdf>

Version: 2024-02-01

27
papers

10,470
citations

516215

16
h-index

552369

26
g-index

27
all docs

27
docs citations

27
times ranked

13323
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1020-1029.	1.9	3
2	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. <i>European Journal of Cancer</i> , 2022, 171, 44-54.	1.3	14
3	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. <i>Lung Cancer</i> , 2021, 156, 147-150.	0.9	4
4	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT48.	1.5	7
5	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
6	Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. <i>Lung Cancer</i> , 2021, 161, 76-85.	0.9	4
7	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
8	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i> -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1396-1404.	1.9	14
9	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer - A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
10	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
11	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	0.8	1,144
12	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Journal of Thoracic Oncology</i> , 2018, 13, 63-72.	0.5	21
13	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236.	1.7	31
14	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 799-811.	5.1	56
15	Looking back and to the future: Are we improving "cure" in non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2017, 75, 192-194.	1.3	13
16	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278.	1.3	22
17	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609.	5.1	282
18	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) \geq 50% enrolled in KEYNOTE-024.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9000-9000.	0.8	43

#	ARTICLE	IF	CITATIONS
19	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 60, 26-39.	1.3	28
20	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	13.9	7,847
21	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. <i>PLoS ONE</i> , 2015, 10, e0139074.	1.1	50
22	Development in the diagnostic lung cancer pathway: implication for treatment. <i>Lung Cancer Management</i> , 2014, 3, 417-428.	1.5	1
23	Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC). <i>BMC Palliative Care</i> , 2014, 13, 59.	0.8	42
24	Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2014, 7, 393-400.	0.3	10
25	Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1882-1888.	0.8	106
26	Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7081-7081.	0.8	1
27	Recent Advances with Topotecan in the Treatment of Lung Cancer. <i>Oncologist</i> , 2007, 12, 1194-1204.	1.9	38